The purpose of this study was to evaluate the efficacy of diffusion-weighted MR imaging with background body signal suppression (DWIBS) and a conventional DWI (cDWI) sequence for the detection of breast lesions. Fifty consecutive patients with suspected breast lesions underwent DWIBS and cDWI at 1.5 T. The routine protocol consisted of a short TI inversion recovery (STIR) sequence and a dynamic contrast-enhanced T1-weighted sequence. Apparent diffusion coefficient (ADC) and exponential ADC (eADC) values of the lesions were calculated. Receiver operating characteristic (ROC) analyses and qualitative evaluation of lesion detectability and conspicuity were performed. Thirty-six lesions were detected in 30 patients by using the routine protocol. DWIBS detected 34 lesions (94%) and cDWI detected 26 lesions (72%). The conspicuity of fibroadenomas was significantly (P = 0.007) better for DWIBS. ADC and eADC values of tumour were significantly different between DWIBS and cDWI. DWIBS is superior to cDWI in the visualization of malignant and benign lesions in the breast.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-009-1426-2DOI Listing

Publication Analysis

Top Keywords

breast lesions
12
diffusion-weighted imaging
8
imaging background
8
background body
8
body signal
8
signal suppression
8
suppression dwibs
8
malignant benign
8
lesions
8
dwibs cdwi
8

Similar Publications

Phyllodes tumor is a type of fibroepithelial neoplasm involving the breast. This tumor is rarely reported in adolescents and the elderly and has a peak incidence in middle-aged women. Histologically, phyllodes tumors are classified as benign, borderline, or malignant.

View Article and Find Full Text PDF

Ductal carcinoma (DCIS), a noninvasive breast cancer, rarely metastasises to distant locations. When the initial lesion is stable, bone marrow metastasis (BMM) and bone marrow necrosis (BMN) are even less common. Here, we report the case of a 47-year-old female patient who underwent localized surgery and radiotherapy for right-sided DCIS.

View Article and Find Full Text PDF

Habitat-based MRI radiomics to predict the origin of brain metastasis.

Med Phys

January 2025

Department of Scientific Research and Academic, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, P. R. China.

Background: This study aims to explore the value of habitat-based magnetic resonance imaging (MRI) radiomics for predicting the origin of brain metastasis (BM).

Purpose: To investigate whether habitat-based radiomics can identify the metastatic tumor type of BM and whether an imaging-based model that integrates the volume of peritumoral edema (VPE) can enhance predictive performance.

Methods: A primary cohort was developed with 384 patients from two centers, which comprises 734 BM lesions.

View Article and Find Full Text PDF

Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from tumor-specific somatic mutation data obtained from tumor tissue of each individual patient to stimulate T cell responses against up to 20 neoantigens. This ongoing phase 1 study evaluated autogene cevumeran as monotherapy (n = 30) and in combination with atezolizumab (n = 183) in pretreated patients with advanced solid tumors.

View Article and Find Full Text PDF

Objective Endometrial lesions are a frequent complication following breast cancer, and current diagnostic tools have limitations. This study aims to develop a machine learning-based nomogram model for predicting the early detection of endometrial lesions in patients. The model is designed to assess risk and facilitate individualized treatment strategies for premenopausal breast cancer patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!